Taipei, Taiwan, 9 October 2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for September 2025 reaching NT$1,214 million, an increase of 2% year-over-year (YoY) compared to same period last year. Lotus's September 2025 year-to-date (YTD) revenue stood at NT$14,248 million, an increase of 1% YoY.
Lotus's Asia business showcased 16% YoY growth for the nine-month ending in September, driven primarily by strong performance in Thailand and Vietnam. Southeast Asian revenue grew 139% compared with the same period prior year. Export markets declined 15% YoY compared to September 2024 YTD, mainly due to peak sales timing of Lenalidomide shifting to Q4 in 2025.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com